Results 61 to 70 of about 5,237,827 (280)
Pediatric Blood &Cancer, EarlyView.ABSTRACT Pediatric gastroenteropancreatic neuroendocrine neoplasms (GEP‐NENs) are extremely rare and clinically heterogeneous. Management has largely been extrapolated from adult practice. This European Standard Clinical Practice Guideline (ESCP), developed by the EXPeRT network in collaboration with adult NEN experts, provides (adult) evidence ...
Michaela Kuhlen +23 more
wiley +1 more source
Carbon Management, 2023 The electronics industry has made remarkable progress over the past 25 years in reducing the emission intensity of long-lived volatile fluorinated compounds (FCs) that typically represent 80 to 90% of uncontrolled direct (scope 1) greenhouse gas (GHG ...
Sébastien Raoux
doaj +1 more source
The development of environmental management systems and corporate responsibility reporting in NZ, UK and USA : a thesis presented in partial fulfilment of the requirements for the degree of Master of Environmental Management at Massey University, New Zealand [PDF]
, 2017 L. C. Martinez. The Development of Environmental Management Systems and Corporate Responsibility Reporting in NZ, UK and USA, 121 pages, 2 figures, 2017.
Martinez, Lucy
core
Criteria for reporting incidental findings in clinical exome sequencing : a focus group study on professional practices and perspectives in Belgian genetic centres [PDF]
, 2019 Background: Incidental and secondary findings (IFs and SFs) are subject to ongoing discussion as potential consequences of clinical exome sequencing (ES). International policy documents vary on the reporting of these findings.
De Baere, Elfride +4 more
core +2 more sources
Pediatric Blood &Cancer, EarlyView.ABSTRACT Purpose Chemoimmunotherapy with irinotecan, temozolomide, and dinutuximab (I/T/DIN) has emerged as first‐line therapy for relapsed/refractory (r/r) high‐risk neuroblastoma (HRNB) in North America. Topotecan and cyclophosphamide (T/C) are often used in combination with dinutuximab in the setting of lack of response, progression, or incomplete ...
Benjamin J. Lerman +17 more
wiley +1 more source
Clinical Course and Impact of Breaks in Therapy for Children With Relapsed/Refractory Solid Tumors
Pediatric Blood &Cancer, EarlyView.ABSTRACT Introduction Pediatric relapsed or refractory (R/R) solid tumors carry a dismal prognosis, and postrelapse patient experiences are not well described. We present postrelapse outcomes, including number of R/R events and subsequent therapy regimens.
Matthew T. McEvoy +5 more
wiley +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Hemoglobinopathies are prevalent globally; diagnosis is complex in high genetic admixture populations like Brazil. We report, in two pediatric siblings, the first documented cases in Brazil of heterozygosity for hemoglobin (Hb) O‐Arab with coinheritance of α‐thalassemia (αα/−α4.2; −α3.7/−α4.2), resulting in microcytic and hypochromic anemia ...
Elisângela de Souza Miranda Muynarsk +9 more
wiley +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Neuropsychological complications may impair the qualitative prognosis of patients with pediatric brain tumors. However, multifaceted evaluations cannot be conducted in all patients because they are time consuming and burdensome for patients.
Ami Tabata +9 more
wiley +1 more source
A review of Australian approaches for monitoring, assessing and reporting estuarine condition: I. International context and evaluation criteria [PDF]
, 2016 © 2016 Elsevier Ltd Given the immeasurable value of estuaries and their severe and growing pressures, sound understanding and reporting of estuarine condition is essential for their effective management and sustainable development.
Elliott, Mike +2 more
core +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Patients with high‐risk neuroblastoma who either are refractory to induction chemotherapy or relapse following multi‐modal treatment have a dismal prognosis. Based on data from the BEACON trial, since 2021 the UK national guidelines recommend bevacizumab, irinotecan, and temozolomide (BIT) for patients with relapsed/refractory ...
Thomas J. Jackson +20 more
wiley +1 more source